Directors Dealings
Directors' Dealings
Personal trades by the Management Board
and Supervisory Board
According to article 19 of Market Abuse Regulation, persons with managerial responsibilities, as well as persons closely related to them, are required to report the purchase and sale of Company shares, or other financial instruments relating thereto, to the German Federal Financial Supervisory Authority (BaFin) and to the Company if the total value of such transactions effected within a calendar year is equal to or more than EUR 5,000.
Such transactions are, in accordance with German law, promptly published by Formycon upon such notification.
General information on the following managers transactions announcements
according to article 19 MAR
Description of the financial instrument: Share
Name of issuer: Formycon AG
ISIN of the financial instrument: DE000A1EWVY8
Legal Entity Identifier (LEI) Code: 39120005TZ76GQOY8Z19
| Date | Name | Position | Transaction | Volume | Price in € | Volume in € | Publication |
|---|---|---|---|---|---|---|---|
| 04/25/2024 | Nicola Mikulcik | Executive Board Member (CBO) | Purchase | 1,200 | 40 | 48,000.00 | Download |
| 04/22/2024 | Dr. Stefan Glombitza | Executive Board Member (CEO) | Purchase | 2,340 | 39 | 91,260.00 | Download |
| 04/22/2024 | Dr. Stefan Glombitza | Executive Board Member (CEO) | Purchase | 160 | 38.65 | 6,184.00 | Download |
| 08/30/2022 | Dr. Stefan Glombitza | Executive Board Member (CEO) | Sale | 15,000 | 76.48 | 1,147,200.00 | Download |
| 08/04/2022 | Dr. Stefan Glombitza | Executive Board Member (CEO) | Purchase | 20,000 | 19.46 | 389,200.00 | Download |
| 03/03/2021 | Dr. Stefan Glombitza | Executive Board Member (COO) | Sale | 15,000 | 64.9 | 973,500.00 | Download |
| 03/03/2021 | Dr. Carsten Brockmeyer | Executive Board Member (CEO) | Sale | 7,500 | 64.9 | 486,750.00 | Download |
| 03/03/2021 | Dr. Nicolas Combé | Executive Board Member (CFO) | Sale | 15,000 | 64.9 | 973,500.00 | Download |
| 02/03/2021 | Dr. Stefan Glombitza | Executive Board Member (COO) | Purchase | 15,000 | 19.46 | 291,900.00 | Download |
| 02/03/2021 | Dr. Carsten Brockmeyer | Executive Board Member (CEO) | Purchase | 7,500 | 20.7 | 155,250.00 | Download |
| 02/03/2021 | Dr. Nicolas Combé | Executive Board Member (CFO) | Purchase | 15,000 | 20.7 | 310,500.00 | Download |
| 11/14/2019 | Peter Wendeln (Wendeln & Cie. KG) | Member of the Supervisory Board | Sale | 72,000 | 30.9 | 2,224,800.00 | Download |
| 07/23/2019 | Dr. Nicolas Combé | Executive Board Member (CFO) | Others | 25,000 | 5.52 | 138,000.00 | Download |
| 07/23/2019 | Dr. Carsten Brockmeyer | Executive Board Member (CEO) | Others | 25,000 | 5.52 | 138,000.00 | Download |
| 06/26/2019 | Peter Wendeln (Wendeln & Cie. KG) | Member of the Supervisory Board | Purchase | 577,397 | 29.9 | 17,264,170.30 | Download |
| 06/05/2019 | Peter Wendeln (Wendeln & Cie. KG) | Member of the Supervisory Board | Others | Not Quantifiable | Not Quantifiable | Not Quantifiable | Download |
| 08/10/2018 | Dr. Nicolas Combé | Executive Board Member (CFO) | Sale | 25,000 | 33.48 | 837,000.00 | Download |
| 08/10/2018 | Dr. Carsten Brockmeyer | Executive Board Member (CEO) | Sale | 25,000 | 33.48 | 837,000.00 | Download |
| 07/21/2018 | Dr. Nicolas Combé | Executive Board Member (CFO) | Purchase | 25,000 | 7.59 | 189,750.00 | Download |
| 07/21/2018 | Dr. Carsten Brockmeyer | Executive Board Member (CEO) | Purchase | 25,000 | 7.59 | 189,750.00 | Download |
| 09/05/2017 | Dr. Nicolas Combé | Executive Board Member (CFO) | Sale | 15,000 | 31.6 | 474,000.00 | Download |
| 09/05/2017 | Dr. Carsten Brockmeyer | Executive Board Member (CEO) | Sale | 15,000 | 31.6 | 474,000.00 | Download |
| 07/14/2017 | Dr. Nicolas Combé | Executive Board Member (CFO) | Purchase | 15,000 | 4.33 | 64,950.00 | Download |
| 07/14/2017 | Dr. Carsten Brockmeyer | Executive Board Member (CEO) | Purchase | 15,000 | 4.33 | 64,950.00 | Download |
Voting Rights Notifications
Voting Rights Notifications
Notifications pursuant to Sections 33 et seq. of the
German Securities Trading Act (WpHG)
Under the German Securities Trading Act (WpHG), the shareholders of a German listed company are obliged to inform the Company and the German Federal Financial Supervisory Authority (BaFin) of any changes in voting rights in Formycon AG if they reach, exceed or fall below the statutory thresholds. The voting rights notifications of Formycon AG are shown in the table below.
We kindly request shareholders who are obliged to submit voting right notifications according to §§ 33ff of the German Securities Trading Act (Wertpapierhandelsgesetz – WpHG) to send their notification in a readable version (pdf) and the XML file and any annexes for the publication of the notification of voting rights in writing to the e-mail address provided below.
| Date | Notifying party | Type of notification | Publication |
|---|---|---|---|
| 13.11.2024 | Klaus Röhrig | Stimmrechtsmitteilung | Download |
| 13.11.2024 | Florian Schuhbauer | Stimmrechtsmitteilung | Download |
| 11/11/2024 | Thomas Peter Maier | Voting Rights Notification | Download |
| 11/11/2024 | Peter Wendeln | Voting Rights Notification | Download |
| 11/11/2024 | Gedeon Richter | Voting Rights Notification | Download |
| 11/11/2024 | Detlef and Ursula Spruth | Voting Rights Notification | Download |
| 11/11/2024 | Stefan R. | Voting Rights Notification | Download |
IR Contact
Contact
Formycon in Dialogue
A key component of our philosophy is the dialogue with capital market players. The Formycon Investor Relations department will be happy to answer any questions or suggestions you may have.
Sabrina Müller
Director Investor Relations and Corporate Communications
T + 49 89 86 46 67 149 ・ F + 49 89 86 46 67 110
We kindly request shareholders who are obliged to submit voting right notifications according to §§ 33ff of the German Securities Trading Act (Wertpapierhandelsgesetz – WpHG) to send their notification in a readable version (pdf) and the XML file and any annexes for the publication of the notification of voting rights in writing to the e-mail address provided below.
We will keep you up to date!
To receive our publications automatically, simply register for the news distribution list.
Governance (IR)
Corporate Governance
Governance at Formycon
Formycon is committed to the principles of good corporate governance in respect of responsible, transparent and long-term successful management and control of the company. We follow the recommendations and principles of the German Corporate Governance Code.
Statutes
With the publication of our annual report 2024, you will also find the declaration of compliance and the remuneration report in this section.
Publications
Financial Reports
Annual, Half-Year and
Quarterly Reports
Key figures and information on the
company's development
9M/2024
Key Financial Figures
Corporate News
Presentation
Earnings-Call
H1/2024
Key Financial Figures
Corporate News
Presentation
Earnings-Call
Financial Report
Q1/2024
Key Financial Figures
Corporate News
Presentation
Earnings-Call
FY 2023
Key Financial Figures
Corporate News
Presentation
Earnings-Call
Financial Report
Q3/2023
Key Financial Figures
Corporate News
Presentation
Earnings-Call
H1/2023
Key Financial Figures
Corporate News
Presentation
Earnings-Call
Financial Report
Financial reports of recent years
Financial Calendar
Financial Calendar
Publications,
Webcasts and Events
Formycon believes in open dialogue with its investors and with the capital markets, as an integral part of its corporate philosophy. In addition to the publication dates for our financial results and the Annual General Meeting, this section provides an overview of the investor conferences that representatives of the Management Board will be attending in the coming weeks.
2025
Ad-Hoc Releases
Ad-Hoc Releases
Disclosure of inside information according to Article 17 of the Regulation (EU) No 596/2014
Formycon Shares
Shares
Creating value with biosimilars
With the commercialization of the next approved biosimilar assets and the continuous expansion of its own development pipeline, Formycon has its sights set on growth and sustainable profitability.
Formycon AG
Share Chart
Basic
Information
| Legal Form | German Stock Corporation (Aktiengesellschaft) |
| Initial Exchange Listing | December 20, 2010 |
| ISIN | DE000A1EWVY8 |
| WKN | A1EWVY |
| Exchange and Market Segment | Regulated Market (Prime Standard) |
| Trading Venues | Xetra, Berlin, Düsseldorf, Frankfurt, Hamburg, Munich, Stuttgart, Tradegate |
| Share Type | Bearer shares without par value |
| Registered Capital | EUR 17,664,427.00 |
| Shares Outstanding | 17,664,427 Bearer shares |
| Designated Sponsors | Oddo BHF Corporates & Markets AG M.M. Warburg & Co |
Shareholder
Structure
Structure as of November 11, 2024
This overview reflects the voting rights notifications pursuant to §§ 33ff of the German Securities Trading Act (Wertpapierhandelsgesetz – WpHG). The individual notifications can be found here.
Analyst
Ratings
| Broker | Rating | Price Target (in EUR) |
|---|---|---|
| Berenberg | buy | 102.0 |
| First Berlin | buy | 82.0 |
| Hauck & Aufhäuser | buy | 90.0 |
| H.C. Wainwright | buy | 90.0 |
| Jefferies | buy | 86.0 |
| Kepler Cheuvreux | buy | 88.4 |
| B. Metzler seel. Sohn & Co. | buy | 82.0 |
| mwb [→ Research Formycon AG] | buy | 89.0 |
| oddo BHF Bank | buy | 80.0 |
| Royal Bank of Canada | buy | 63.0 |
| M.M. Warburg Bank | buy | 89.0 |
Formycon is covered and evaluated by the analysts mentioned above. Please note that any opinions, estimates or forecasts regarding Formycon’s performance made by these analysts are theirs alone and do not represent opinions, estimates or forecasts of Formycon or its management. The above reference to the analysts does not imply that Formycon endorses their opinions. Formycon is under no obligation to update or supplement the information provided above and does not guarantee the accuracy or completeness of this list.
Analysten Consensus
■ 24,05 % Santo Holding (Deutschland) GmbH, Thomas Peter Maier
■ 13,26 % Wpart GmbH, Wen.Co Invest GmbH, Peter Wendeln
■ 9,08 % Richter Gedeon Vegyészeti Gyár Nyilvánosan Müködö Rt. (Gedeon Richter)
■ 6,04 % Active Ownership Fund SICAV SIF SCS, Klaus Röhrig, Florian Schuhbauer
■ 5,10 % Detlef und Ursula Spruth
■ 3,28 % Stefan Reichensperger
■ 39,19 % Streubesitz